Clinical Trial: Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Trial of Sunitinib in Bronchoalveolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma
Brief Summary: This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.
Detailed Summary: To participate in this study, patients must have disease that can be measured on a CT scan. Brain metastases are OK if stable. Pregnant and/or nursing women may not participate. This drug has been approved by the FDA for the treatment of advanced renal cell cancer and a certain type of stomach/intestinal cancer. Its efficacy in lung cancer in currently unknown. Common side effects include fatigue, nausea, diarrhea, skin reaction, and decreased blood counts.
Sponsor: Swedish Medical Center
Current Primary Outcome: Progression-Free Survival [ Time Frame: January 2009 ]
Original Primary Outcome:
- Progression-Free Survival
- Time to Progression
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Swedish Medical Center
Dates:
Date Received: January 30, 2007
Date Started: January 2007
Date Completion:
Last Updated: October 5, 2010
Last Verified: October 2010
